Evidence map›Paper›PMID 24167449›Full record

ArticlePLoS medicine2013

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study.

Jan A C Hontelez, Mark N Lurie, Till Bärnighausen, Roel Bakker, Rob Baltussen, Frank Tanser, Timothy B Hallett, Marie-Louise Newell, Sake J de Vlas

Abstract read
In one paragraph

Article in PLoS medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jan A C HontelezDepartment of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, Netherlands ; Nijmegen International Center for Health System Analysis and Education, Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands ; Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa.
Mark N Lurie
Till Bärnighausen
Roel Bakker
Rob Baltussen
Frank Tanser
Timothy B Hallett
Marie-Louise Newell
Sake J de Vlas

Funding

Spatial Analysis CoreR24HD041020 · NICHD · BROWN UNIVERSITY · PI LOGAN, JOHN R · 2001 to 2016
$7.4M
Impact of Antiretroviral Therapy on HIV Epidemic DynamicsR01MH083539 · NIMH · BROWN UNIVERSITY · PI LURIE, MARK NATHAN · 2009 to 2012
$2.2M
Understanding causal pathways of HIV acquisition and transmission: a multi-level,R01HD058482 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2008 to 2012
$1.2M
Medical Research Council MR/K010174/1NICHD NIH HHS R01 HD058482NICHD NIH HHS R24 HD041020NIMH NIH HHS R01 MH083539Wellcome Trust 097410
6 · The paper itself

Abstract

backgroundExpanded access to antiretroviral therapy (ART) using universal test and treat (UTT) has been suggested as a strategy to eliminate HIV in South Africa within 7 y based on an influential mathematical modeling study. However, the underlying deterministic model was criticized widely, and other modeling studies did not always confirm the study's finding. The objective of our study is to better understand the implications of different model structures and assumptions, so as to arrive at the best possible predictions of the long-term impact of UTT and the possibility of elimination of HIV. METHODS AND

findingsWe developed nine structurally different mathematical models of the South African HIV epidemic in a stepwise approach of increasing complexity and realism. The simplest model resembles the initial deterministic model, while the most comprehensive model is the stochastic microsimulation model STDSIM, which includes sexual networks and HIV stages with different degrees of infectiousness. We defined UTT as annual screening and immediate ART for all HIV-infected adults, starting at 13% in January 2012 and scaled up to 90% coverage by January 2019. All models predict elimination, yet those that capture more processes underlying the HIV transmission dynamics predict elimination at a later point in time, after 20 to 25 y. Importantly, the most comprehensive model predicts that the current strategy of ART at CD4 count ≤350 cells/µl will also lead to elimination, albeit 10 y later compared to UTT. Still, UTT remains cost-effective, as many additional life-years would be saved. The study's major limitations are that elimination was defined as incidence below 1/1,000 person-years rather than 0% prevalence, and drug resistance was not modeled.

conclusionsOur results confirm previous predictions that the HIV epidemic in South Africa can be eliminated through universal testing and immediate treatment at 90% coverage. However, more realistic models show that elimination is likely to occur at a much later point in time than the initial model suggested. Also, UTT is a cost-effective intervention, but less cost-effective than previously predicted because the current South African ART treatment policy alone could already drive HIV into elimination. Please see later in the article for the Editors' Summary.

Indexed as

Models, TheoreticalAdultAnti-HIV AgentsFemaleHIV InfectionsHumansMaleSouth AfricaAnti-HIV Agents

Identifiers

PMID24167449
PMCPMC3805487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.